Authors: Serov N.S., Prilepskii A.Y., Alexey Sokolov, Vinogradov V.V.
Abstract
A major obstacle in the development of the next‐generation of thrombolytic drugs has been the fact that plasmin – a serine protease that dissolves fibrin in blood clots – despite being the only enzyme suitable for the clot cleavage, is still not used in practice due to its rapid inactivation. Here we point to a potential solution to this problem by developing a magnetically controlled system for targeted delivery and recrystallization‐driven release of plasmin showing therapeutic potential.
DOI: https://doi.org/10.1002/cnma.201900359
Read full: https://onlinelibrary.wiley.com/doi/full/10.1002/cnma.201900359